As of Oct 20
| +0.12 / +7.45%|
The 3 analysts offering 12-month price forecasts for Aevi Genomic Medicine Inc have a median target of 5.00, with a high estimate of 7.00 and a low estimate of 1.50. The median estimate represents a +189.02% increase from the last price of 1.73.
The current consensus among 3 polled investment analysts is to Buy stock in Aevi Genomic Medicine Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.